aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Chroma Medicine is a genomic medicine company focused on pioneering a new class of treatments that harness epigenetics, nature’s innate mechanism for gene regulation. Their mission is to revolutionize the treatment of genetically driven diseases by developing innovative therapies that precisely target gene expression.
Chroma Medicine has made significant strides in the field of genomic medicine, leveraging cutting-edge research to create impactful solutions for genetic disorders. Their work has the potential to transform patient outcomes and advance the broader field of gene therapy.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Genomic Medicines
Technology
Biotech, GenAI
Model Types
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Chroma Medicine founded?
Chroma Medicine was founded in 2021.
Where is Chroma Medicine’s headquarters located?
Chroma Medicine’s headquarters is located in Cambridge, MA, US.
When was Chroma Medicine’s last funding round?
Chroma Medicine’s most recent funding round was for $135M (USD) in March 2023.
How many employees does Chroma Medicine have?
Chroma Medicine has 137 employees as of Feb 5, 2024.
How much has Chroma Medicine raised to-date?
As of July 05, 2023, Chroma Medicine has raised a total of $260M (USD) since Mar 1, 2023.
Add Comparison
Total Raised to Date
$260M
USD
Last Update Mar 1, 2023
Last Deal Details
$135M
USD
Mar 1, 2023
Series B
Total Employees Over Time
137
As of Feb 2024
Chroma Medicine Address
1 Kendall Square
Cambridge,
Massachusetts
02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts